Anti-SARS-CoV-2 Spike glycoprotein mAb (Clone: A2-5A12)

Cosmo Bio LTD

Catalog No: HAK-ANTI-SPD-MAB-1

When the new coronavirus infects a cell, the spike protein on the surface of the virus binds to ACE2 on the cell surface. Drugs that block this binding will prevent viral infection.

1. ACE2 extracellular domain
2. SARS-CoV-2 spike protein RBD/rabbit Fc tag
3. Biotinylated SARS-CoV-2 spike protein RBD and rabbit Fc tag
4. Neutralizing antibodies

We have also started selling a monoclonal antibody ( anti-SARS-CoV-2 spike protein monoclonal antibody (mouse)

) that is specific and has high affinity to the receptor binding domain of the spike protein S1 domain . This is a neutralizing antibody that inhibits the binding of the receptor binding domain to ACE2. 

• We also offer mutant strains. 

 

SARS-CoV-2 spike protein RBD/rabbit Fc tag

Biotinylated SARS-CoV-2 spike protein RBD and rabbit Fc tag

Background

Angiotensin-converting enzyme 2 (ACE2), also known as ACE homolog, is an integral membrane protein that is highly homologous to ACE. ACE2 was known as one of the factors that work in the renin-angiotensin system, which is involved in blood pressure regulation. Recently, it has been revealed that when the novel coronavirus that causes COVID-19 infects human cells, it binds to ACE2 present in the cell membrane and is then taken into the cell, and ACE2 is also thought to be a receptor for the novel coronavirus. ⁽¹⁾ A highly sensitive binding assay is provided by immobilizing
human ACE2 protein with His tag (product number: HAK-ACE2_UL-1) on a 96-well plate and adding SARS-CoV-2 spike protein RBD with rabbit Fc tag (product number: HAK-SPD_UL-1) or biotinylated SARS-CoV-2 spike protein RBD with rabbit Fc tag (product number: HAK-SPD_bio-1), which is a fusion protein in which the receptor binding domain of the viral protein is bound to rabbit Fc, and detecting with an HRP-labeled secondary antibody or streptavidin.

 

 

Neutralizing antibodies

Using a unique antibody screening method using exosomes expressing the full-length spike protein of SARS-CoV-2, we obtained a monoclonal antibody that inhibits the binding of the spike protein to ACE2. Furthermore, we determined the structure of the variable region, and expressed and purified a chimeric antibody with the human constant region (IgG1) in animal cells. Both antibodies showed strong binding inhibitory activity using binding assay reagents.

• Anti-SARS-CoV-2 spike protein monoclonal antibody (mouse)
• Anti-SARS-CoV-2 Spike Protein Recombinant Chimeric Antibody (Human/Mouse)

Anti-SARS-CoV-2 spike protein monoclonal antibody (mouse)

Product Information

Antibody Information
Clone name: A2-5A12 Antibody details: Anti-SARS-CoV-2 spike protein monoclonal antibody Class: IgG1/κ Immunogen: Recombinant SARS-CoV-2 spike protein (Val327~Thr531) Source: Mouse Applications: ELISA, spike protein/ACE2 binding inhibition experiments
concentration
Approximately 1mg/mL
composition
0.1M-PBS (pH 7.2~7.4), 0.2µm filter
keep
Avoid repeated freeze-thaw cycles. Upon receipt, store product at -70°C or colder. Aliquoting is recommended prior to use.

 

Usage Example

1. Inhibition of binding between spike protein and ACE2
• Biotin-labeled receptor binding domain protein diluted to 500ng/mL and anti-SARS-CoV-2 virus spike protein antibody (this product) (3.1, 9.1, 27.4, 82.3, 247, 741, 2222, 6667, 20000ng/mL) as a binding inhibitor were added to a 96-well microplate with ACE2 protein immobilized, and the reaction was allowed to proceed for 2 hours at room temperature. As a comparison antibody, a commercially available anti-SARS-CoV-2 virus spike protein monoclonal antibody from another company was used.
  After reaction with each antibody, the plate was washed, and HRP-labeled streptavidin and a color-developing substrate were added and reacted. After adding a stop solution, the absorbance of each well was measured. As a result, both antibodies inhibited the binding of the spike protein receptor-binding domain to ACE2, but the IC50 values ​​of this product and the competitor's antibody were 23.6 ng/mL and 1270 ng/mL, respectively, demonstrating that the inhibitory activity of this product was 53.8 times stronger than that of the competitor's antibody (Figure 8).

Figure 8. Inhibition of binding between spike protein and ACE2